Table 2.
Treatment Outcomes of IFX in Hospitalized Patients with Acute Severe Ulcerative Colitis, According to IFX Indication
| Variable | IFX-rescuea (n = 37) | IFX-initialb (n = 12) | P-value |
|---|---|---|---|
| Short-termc | |||
| Clinical remission | 3 (23.1) | 3 (30.0) | 1.000 |
| Rehospitalizatioin | 7 (18.9) | 3 (25.0) | 0.690 |
| Colectomy | 3 (8.1) | 0 | 0.566 |
| Long-termd | |||
| Clinical remissione | 7 (46.7) | 3 (42.9) | 1.000 |
| Rehospitalization | 15 (41.7) | 4 (33.3) | 0.740 |
| Colectomy | 7 (18.9) | 2 (16.7) | 1.000 |
Values are presented as number (%).
a
Infliximab (IFX) as rescue therapy after failure of intravenous corticosteroids.
b
IFX as first-line therapy for acute severe ulcerative colitis.
c
At 3 months of follow-up.
d
At the end of follow-up.
e
At 12 months of follow-up.